# CD19-CAR-T Cells in Patients With R/R B-ALL

> **NCT03574168** · PHASE1 · UNKNOWN · sponsor: **Bioceltech Therapeutics, Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** CD19-CAR-T Cells

## Key facts

- **NCT ID:** NCT03574168
- **Lead sponsor:** Bioceltech Therapeutics, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-20
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2018-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03574168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03574168, "CD19-CAR-T Cells in Patients With R/R B-ALL". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03574168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*